

Journalbeiträge

1. Alves F, Dullin C, Napp J, Missbach-Guentner J, Jannasch K, Mathejczyk J, Pardo LA, Stühmer W, Tietze LF (2009) Concept of a selective tumour therapy and its evaluation by near-infrared fluorescence imaging and flat-panel volume computed tomography in mice. *EUR J RADIOL*, 70(2): 286-93.
2. Bernd HW, Ziepert M, Thorns C, Klapper W, Wacker HH, Hummel M, Stein H, Hansmann ML, Ott G, Rosenwald A, Müller-Hermelink HK, Barth TFE, Möller P, Cogliatti SB, Pfreundschuh M, Schmitz N, Trümper L, Höller S, Löffler M, Feller AC (2009) Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. *Haematol-Hematol J (Internet-Ausgabe)*, 94(11): 1569-80.
3. Binder C, Hagemann T, Sperling S, Schulz M, Pukrop T, Grimshaw MJ, Ehrenreich H (2009) Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis. *MOL CANCER THER*, 8(8): 2452-60.
4. Blalock WL, Grimaldi C, Fala F, Follo M, Horn S, Basecke J, Martinelli G, Cocco L, Martelli AM (2009) PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. *J Cell Physiol (Internet-Ausgabe)*, 221(1): 232-41.
5. Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W (2009) The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). *LEUKEMIA*, 23(1): 153-61.
6. Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, Wulf GG (2009) ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. *Haematol-Hematol J (Internet-Ausgabe)*, 94(11): 1528-36.
7. Dellas C, Chapuy B, Schweyer S, Hasenfuss G, Hünlich M (2009) A rare cause of sudden cardiac arrest: primary cardiac lymphoma. *Clin Res Cardiol (Internet-Ausgabe)*, 98(8): 509-11.
8. Dullin C, Zientkowska M, Napp J, Missbach-Guentner J, Krell HW, Müller F, Grabbe E, Tietze LF, Alves F (2009) Semiautomatic landmark-based two-dimensional-three-dimensional image fusion in living mice: correlation of near-infrared fluorescence imaging of Cy5.5-labeled antibodies with flat-panel volume computed tomography. *MOL IMAGING BIOL*, 8(1): 2-14.
9. Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. *J Clin Oncol (Internet-Ausgabe)*, 27(27): 4548-54.
10. Fischer M, Grünwald F, Knapp WH, Trümper L, von Schilling C, Dreyling M (2009) [Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin's lymphoma.]. *NUKLEARMED-NUCL MED*, 48(6): 215-20.
11. Fritzmann J, Morkel M, Besser D, Budczies J, Kosel F, Brembeck FH, Stein U, Fichtner I, Schlag PM, Birchmeier W (2009) A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. *Gastroenterology (Internet-Ausgabe)*, 137(1): 165-75.
12. Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M (2009) Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma. *ONCOLOGIST*, 14 Suppl 2: 4-16.
13. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. *J CLIN ONCOL*, 27(4): 511-8.
14. Hossain MA, Samuel CS, Binder C, Hewitson TD, Tregear GW, Wade JD, Bathgate RAD (2009) The chemically synthesized human relaxin-2 analog, B-R13/17K H2, is an RXFP1 antagonist. *AMINO ACIDS*, in press: in press.
15. Jannasch K, Dullin C, Heinlein C, Krepulat F, Wegwitz F, Deppert W, Alves F (2009) Detection of different tumor growth kinetics in single transgenic mice with oncogene-induced mammary carcinomas by flat-panel volume computed tomography. *INT J CANCER*, 125(1): 62-70.
16. Kaune KM, Baumgart M, Schmitke E, Haase D, Middel P, Ghadimi BM, Bertsch HP, Neumann C, Emmert S (2009) Papular exanthem discloses acute myeloid leukaemia: interphase fluorescence in situ hybridization revealed deletion of p53 and gain at 8q22/8q24/Tel8q without trisomy 8. *Clin Exp Dermatol (Internet-Ausgabe)*, -: -.
17. Kaune KM, Baumgart M, Bertsch HP, Mitteldorf C, Müller-Hermelink HK, Haase D, Ghadimi BM, Schön MP, Neumann C (2009) Solitary cutaneous nodule of blastic plasmacytoid dendritic cell neoplasm progressing to overt leukemia cutis after chemotherapy: immunohistology and FISH analysis confirmed the diagnosis. *Am J Dermatopath (Internet-Ausgabe)*, 31(7): 695-701.

18. Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood* (Internet-Ausgabe), 114(26): 5264-70.
19. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT (2009) The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. *Breast Cancer Res Tr* (Internet-Ausgabe), 116(2): 225-37.
20. Martin-Subero JL, Ammerpohl O, Bibikova M, Wickham-Garcia E, Agirre X, Alvarez S, Brüggemann M, Bug S, Calasanz MJ, Deckert M, Dreyling M, Du MQ, Dürig J, Dyer MJS, Fan JB, Gesk S, Hansmann ML, Harder L, Hartmann S, Klapper W, Küppers R, Montesinos-Rongen M, Nagel I, Pott C, Richter J, Román-Gómez J, Seifert M, Stein H, Suela J, Trümper L, Vater I, Prosper F, Haferlach C, Cruz Cigudosa J, Siebert R (2009) A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. *PLoS One*, 4(9): e6986.
21. Martín-Subero JL, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, Wickham-Garcia E, Rosolowski M, Richter J, Lopez-Serra L, Ballestar E, Berger H, Agirre X, Bernd HW, Calvanese V, Cogliatti SB, Drexler HG, Fan JB, Fraga MF, Hansmann ML, Hummel M, Klapper W, Korn B, Küppers R, Macleod RAF, Möller P, Ott G, Pott C, Prosper F, Rosenwald A, Schwaenen C, Schübeler D, Seifert M, Stürzenhocke B, Weber M, Wessendorf S, Loeffler M, Trümper L, Stein H, Spang R, Esteller M, Barker D, Hasenclever D, Siebert R (2009) New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. *BLOOD*, 113(11): 2488-97.
22. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA (2009) Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. *LEUKEMIA*, 23(1): 25-42.
23. Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, Mueller-Hermelink HK, Pfreundschuh M, Schmitz N (2009) High-dose CHOP plus etoposide (MegaCHOP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). *Ann Oncol* (Internet-Ausgabe), -: -.
24. Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, Lübbert M, Stauder R, Giagounidis A, Valent P, Pfeilstöcker M (2009) Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. *Ann Oncol* (Internet-Ausgabe), -: -.
25. Pfriem M, Overbeck T, Hohloch K, Tondrow M, Hoerauf H (2009) [A case of bilateral optic disc edema]. *KLIN MONATSBL AUGENH*, 226(2): 130-1.
26. Piesche M, Hildebrandt Y, Chapuy B, Wulf GG, Trümper L, Schroers R (2009) Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3. *VACCINE*, 27(34): 4718-23.
27. Pukrop T, Bleckmann A, Einspanier A, Binder C (2009) Rapid progression of hormone receptor-negative breast cancer concomitant with ovarian stimulation--a paradoxon? *Ann Oncol* (Internet-Ausgabe), 20(12): 2020-2.
28. Raupach T, Muenscher C, Anders S, Steinbach R, Pukrop T, Hege I, Tullius M (2009) Web-based collaborative training of clinical reasoning: a randomized trial. *MED TEACH*, 31(9): e431-7.
29. Raupach T, Münscher C, Pukrop T, Anders S, Harendza S (2009) Significant increase in factual knowledge with web-assisted problem-based learning as part of an undergraduate cardio-respiratory curriculum. *Adv Health Sci Educ* (Internet-Ausgabe), ? : ?.
30. Raupach T, Anders S, Pukrop T, Hasenfuss G, Harendza S (2009) Effects of "minimally invasive curricular surgery" - a pilot intervention study to improve the quality of bedside teaching in medical education. *MED TEACH*, 31(9): e425-30.
31. Raupach T, Spering C, Bäuml C, Burckhardt G, Trümper L, Pukrop T (2009) Hochschuldidaktische Fortbildung in der Universitätsmedizin: ein Beitrag zur Bedarfsanalyse. *MED KLIN*, 104(11): 841-5.
32. Schanz J, Jung H, Wörmann B, Gassmann W, Petersen T, Hinke A, Haase D (2009) Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes. *Leukemia Res* (Internet-Ausgabe), 33(9): 1183-8.
33. Schoof N, von Bonin F, König IR, Mössner R, Krüger U, Reich K, Berking C, Volkenandt M, Ziegler A, Böckmann L, Kuschal C, Thoms KM, Kube D, Emmert S (2009) Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case--control study. *Genes Immun* (Internet-Ausgabe), -: -.
34. Schoof N, von Bonin F, Zeynalova S, Ziepert M, Jung W, Loeffler M, Pfreundschuh M, Trümper L, Kube D (2009) Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. *Ann Oncol* (Internet-Ausgabe), -: -.
35. Schoof N, von Bonin F, Trümper L, Kube D (2009) HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells. *Cell Commun Signal*, 7: 17.

36. Schwaenen C, Viardot A, Berger H, Barth TFE, Bentink S, Döhner H, Enz M, Feller AC, Hansmann ML, Hummel M, Kestler HA, Klapper W, Kreuz M, Lenze D, Loeffler M, Möller P, Müller-Hermelink HK, Ott G, Rosolowski M, Rosenwald A, Ruf S, Siebert R, Spang R, Stein H, Truemper L, Lichter P, Bentz M, Wessendorf S (2009) Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. *Gene Chromosome Canc* (Internet-Ausgabe), 48(1): 39-54.
37. Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. *J Clin Oncol* (Internet-Ausgabe), 27(24): 3994-4001.
38. Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A (2009) Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. *Oncogene* (Internet-Ausgabe), -: -.
39. Trappe R, Hinrichs C, Appel U, Babel N, Reinke P, Neumayer HH, Budde K, Dreyling M, Dührsen U, Kliem V, Schüttrumpf S, Hauser IA, Mergenthaler HG, Schlattmann P, Anagnostopoulos I, Doerken B, Riess H (2009) Treatment of PTLN with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. *AM J TRANSPLANT*, 9(10): 2331-7.
40. Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U (2009) Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes. *ANN HEMATOL*, 88(7): 607-11.
41. van de Loosdrecht AA, Alhan C, Béné MC, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subirá D, Valent P, van der Velden VHJ, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, Westers TM (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometric in myelodysplastic syndromes. *Haematol-Hematol J* (Internet-Ausgabe), -: -.
42. von Ahsen N, Binder C, Brockmöller J, Oellerich M (2009) CYP2D6 und Tamoxifen: pharmakogenetische Neuentdeckung eines etablierten Medikaments? *Laboratoriumsmedizin*, 33 (5): 293-302.
43. Wolff H, Overbeck T, Roedel R, Hermann R, Herrmann M, Kertesz T, Vorwerk H, Hille A, Matthias C, Hess C, Christiansen H (2009) Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. *J CANCER RES CLIN*, 135(7): 961-7.

### Medizinische Dissertationen

1. Anke J, Dr. med., AML-assoziierte Aberrationen bei Gesunden und nach Chemotherapie. Dissertation Universität Göttingen 2009.
2. David A, Dr. med., Die Bedeutung von ZAP-70 als Prognosefaktor bei der chronischen lymphatischen B-Zell-Leukämie. Dissertation Universität Göttingen 2009.
3. Goldstein J, Dr. med., Leukämie-assoziierte Aberrationen im Nabelschnurblut. Dissertation Universität Göttingen 2009.
4. Hua T, Dr. med., Assoziation von Genpolymorphismen der 5' flankierenden Region des Interleukin-10-Gens auf das Überleben oder die Remissionsrate beim aggressiven Non-Hodgkin-Lymphom. Dissertation Universität Göttingen 2009.
5. Hüser A, Dr. med., Molekulare Analyse der Immunglobulingene aggressiver Non-Hodgkin-Lymphome. Dissertation Universität Göttingen 2009.
6. Kirchhof S, Dr. med., Durchflusszytometrische Charakterisierung von Leukaphereseprodukten bei Patienten mit akuter myeloischer Leukämie zur Detektion von "minimal residual disease". Dissertation Universität Göttingen 2009.
7. Koch R, Dr. med., Die Rolle des ABC-Transporters A3 für den Resistenzmechanismus der subzellulären Zytostatikasequestrierung. Dissertation Universität Göttingen 2009.
8. Radunski U, Dr. med., Analyse der prognostischen Relevanz der Expression des ABC-Transporters A3 in leukämischen Zellen von Patienten mit myeloischen Leukämien. Dissertation Universität Göttingen 2009.

### Zahnmedizinische Dissertationen

1. Rennspieß-Wilkens M, Dr. med. dent., Nachweis des CFBF-MYH11-Fusionsgens (inv(16)(p13;q22)) in Nabelschnurblut. Dissertation Universität Göttingen 2009.